The purpose of this study is to assess the safety and effectiveness dextroamphetamine to help methamphetamine users quit or cut down on their use. The study lasts for 9 weeks. Eligible participants will attend research visits twice per week, and will receive individual counseling sessions once per week for all 9 weeks. 50% of the participants will receive the active medication while the other 50% will receive the placebo (sugar pill). Neither the participant or the study team will know if the participant is receiving the placebo or active drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
1 week placebo and 8 weeks 60mg d-AMP QD.
9 weeks of placebo 60mg capsules QD.
CPMC-St. Luke's Campus-Addiction Pharmacology Research Laboratory
San Francisco, California, United States
Subjects treated with dextroamphetamine will have better outcomes than subjects treated with placebo, as indicated by the number of urine samples that do not indicate new use of MA (the primary outcome measure)
Time frame: Twice per week for 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.